ACLX News and Press, Arcellx Inc. From 05/09/22

Arcellx Announces Publication in Blood Advances of Clinical Results from the Dose Escalation Cohorts of its CART-ddBCMA Phase 1 Study in Patients with Relapsed or Refractory Multiple Myeloma PR Newswire 100% ORR ; 75% CR/sCR; and evidence of durable clinical benefit ...

Arcellx Announces Participation at the BofA Securities 2022 Healthcare Conference PR Newswire FOSTER CITY, Calif. , May 5, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of ...

Arcellx to Present New Clinical Data from its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma in an Oral Abstract Session at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting PR Newswire -- Company to host a live webc...

Arcellx (ACLX) shares jumped 12% on Monday following a week of declines. Shares of the biotech group opened at $11.23 and hit a high of $11.97 in early afternoon. The stock recently changed hands at $11.94, up 12%, at approximately 1:15 p.m. Based in Maryland, Arcellx has been developing cell...

Arcellx Presents Pre-Clinical Data for ACLX-002, a Novel CD123-targeted Universal CAR-T Cell Therapy for Relapsed or Refractory Acute Myeloid Leukemia at the American Association for Cancer Research Annual Meeting PR Newswire -- ACLX-002 completely regresses multiple c...

Arcellx press release (NASDAQ:ACLX): FY Cash cash and euivalents $104.6M Net loss of $65M. For further details see: Arcellx reports FY results

Arcellx Provides Business Update and Reports Fourth Quarter and Year-End 2021 Financial Results PR Newswire -- Completed upsized initial public offering of common stock, raising $142.3 million in gross proceeds including full exercise of underwriters' option to purch...

Arcellx (ACLX) stock hit a 52-week low on Tuesday before modestly moving higher in late morning trading. Shares of the biotech group recently changed hands at $15.09, up 3% at approximately 11:00 a.m. ET. Arcellx shares opened at $14.52, sinking to a 52-week low of $14.18 before moving higher...

Arcellx Announces Participation at the Barclays Global Healthcare Conference PR Newswire FOSTER CITY, Calif. , March 10, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a clinical-stage cell therapy biotechnology company, announced today that chairman and chie...

Arcellx Announces Pre-Clinical Data Presentation for ACLX-002, a Novel CD123-targeted Universal CAR-T Cell Therapy for Relapsed or Refractory Acute Myeloid Leukemia at the American Association for Cancer Research Annual Meeting 2022 PR Newswire FOSTER CITY, Calif. , ...